25243-95-2
25243-95-2
Chemical Structure
L-Octanoylcarnitine
- CAS No.: 25243-95-2
- Formula:C15H29NO4
- Molecular Weight:287.40
IUPAC Name: (R)-3-(octanoyloxy)-4-(trimethylammonio)butanoate
InChIKey: CXTATJFJDMJMIY-CYBMUJFWSA-N
SMILES: CCCCCCCC(O[C@H](CC([O-])=O)C[N+](C)(C)C)=O
Biological Activity: L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
L-Octanoylcarnitine | 98.0% | L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Octanoylcarnitine (Standard) | ≥98% | L-Octanoylcarnitine (Standard) is the analytical standard of L-Octanoylcarnitine. This product is intended for research and analytical applications. L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Octanoylcarnitine-d3 | L-Octanoylcarnitine-d3 is the deuterium-labeled L-Octanoylcarnitine (HY-113161). L-Octanoylcarnitine-d3 is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine-d3 can be used for the research of breast cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Octanoylcarnitine-d9 | 99.9% | L-Octanoylcarnitine-d9 is deuterium labeled L-Octanoylcarnitine. L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer.. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kim M, et al. Association between arterial stiffness and serum L-octanoylcarnitine and lactosylceramide in overweight middle-aged subjects: 3-year follow-up study. PLoS One. 2015 Mar 17;10(3):e0119519. [Content Brief]
- [2]. Schönfeld P, Reiser G. Inhibition of β-oxidation is not a valid therapeutic tool for reducing oxidative stress in conditions of neurodegeneration. J Cereb Blood Flow Metab. 2017 Mar;37(3):848-854. [Content Brief]
- [3]. Hanna Kosnik, et al. CHRONIC HIGH FAT DIET IMPAIRS DETRUSOR MITOCHONDRIAL FATTY ACID OXIDATION IN MALE BUT NOT FEMALE MICE. Journal of UrologyBladder & Urethra: Anatomy, Physiology & Pharmacology I (MP11)1 Apr 2019.
